Shares of Eli Lilly and Novo Nordisk jumped in premarket trading after Hims & Hers said that the company will not sell its copycat weight-loss pill.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results